en

PRODUCT DETAIL

Bortezomib EVER Pharma 2,5 mg/ml injekčný roztok

Code 3027E
MA number 44/0062/23-S
Product Form: sol inj 1x1,4 ml/3,5 mg (liek.inj.skl.)
MA Status: R - Valid Marketing Authorisation
Type of procedure: Mutual recognition procedure
Therapeutic Class: 44 - CYTOSTATICA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XG Proteasome inhibitors
L01XG01 Bortezomib
Shelf life: 18
Container: glass vial
Route of admin.: Subcutaneous and intravenous use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 10(3) hybrid application
MA issued: 11.03.2023
Validity: 11.03.2028
SPC: SPC _Bortezomib EVER Pharma_02 2023.pdf  
PIL: PIL_Bortezomib EVER Pharma 2,5 mg_ml injekčný roztok_10.2023.pdf  
Safety feature Yes
Data update: 21.03.2023
eu-flag.png sk-flag.png